Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (15)

« Back to Publications

Systemic immune-metabolic interactions in patients with amyotrophic lateral sclerosis: correlations of plasma cytokines with metabolic status

Howe SL. et al, (2026), Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 1 - 11

Lower-limb biomechanics in motor neuron disease: a joint-level perspective of gait disruption

Holdom CJ. et al, (2026), Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 27, 44 - 54

Examining the impact and role of lipid classes on the risk of amyotrophic lateral sclerosis (ALS) onset: a systematic review and GRADE analysis of the evidence

Sewell-Green AR. et al, (2025), Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 1 - 13

Persistent high levels of perceived fatigue are not associated with hypermetabolism in patients with amyotrophic lateral sclerosis

Buckett LE. et al, (2025), Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 26, 485 - 494

The Use of Digital Devices to Monitor Physical Behavior in Motor Neuron Disease: Systematic Review

Musson LS. et al, (2025), Journal of Medical Internet Research, 27, e68479 - e68479

Non-traditional biomarkers for motor neuron disease

Holdom C., (2025)

The Use of Digital Devices to Monitor Physical Behavior in Motor Neuron Disease: Systematic Review (Preprint)

Musson LS. et al, (2024)

Variation in Resting Metabolic Rate Affects Identification of Metabolic Change in Geographically Distinct Cohorts of Patients With ALS

Holdom CJ. et al, (2024), Neurology, 102

Associations of postprandial ghrelin, liver‐expressed antimicrobial peptide 2 and leptin levels with body composition, disease progression and survival in patients with amyotrophic lateral sclerosis

Howe SL. et al, (2024), European Journal of Neurology, 31

Use of hip- versus wrist-based actigraphy for assessing functional decline and disease progression in patients with motor neuron disease

Holdom CJ. et al, (2023), Journal of Neurology, 270, 2597 - 2605

Lower hypothalamic volume with lower body mass index is associated with shorter survival in patients with amyotrophic lateral sclerosis

Chang J. et al, (2023), European Journal of Neurology, 30, 57 - 68

Patient perspectives on digital healthcare technology in care and clinical trials for motor neuron disease: an international survey

Helleman J. et al, (2022), Journal of Neurology, 269, 6003 - 6013

Low plasma hyaluronan is associated with faster functional decline in patients with amyotrophic lateral sclerosis

Holdom CJ. et al, (2022), Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 23, 42 - 48

Biofluid Biomarkers of Amyotrophic Lateral Sclerosis

Holdom CJ. et al, (2022), 263 - 306

Venous creatinine as a biomarker for loss of fat‐free mass and disease progression in patients with amyotrophic lateral sclerosis

Holdom CJ. et al, (2021), European Journal of Neurology, 28, 3615 - 3625